Chemistry:INCB086550
From HandWiki
INCB086550 is a drug that is a small-molecule inhibitor of programmed death-ligand 1 (PD-L1). A number of antibodies against this target are already in clinical use for cancer treatment, but few small molecule drugs are known. INCB086550 enhances the T-lymphocyte mediated immune response against cancers which express PD-L1, and induces cytokine production. It has been researched for the treatment of cancers such as breast cancer and colorectal cancer.[1][2][3][4]
References
- ↑ "Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor". Cancer Discovery 12 (6): 1482–1499. June 2022. doi:10.1158/2159-8290.CD-21-1156. PMID 35254416.
- ↑ "Dual inhibition of TYK2 and PD-L1 boosts immune response in triple negative breast cancer". Anti-Cancer Drugs 36 (4): 280–289. April 2025. doi:10.1097/CAD.0000000000001685. PMID 39774369.
- ↑ "Characterization of Clinically Evaluated Small-Molecule Inhibitors of PD-L1 for Immunotherapy". ACS Medicinal Chemistry Letters 16 (7): 1359–1364. July 2025. doi:10.1021/acsmedchemlett.5c00245. PMID 40666457.
- ↑ "Small-Molecule Inhibitors Targeting PD-1/PD-L1 in Colorectal Cancer: Mechanisms, Challenges, and Clinical Prospects". ChemMedChem 21 (1). January 2026. doi:10.1002/cmdc.202500738. PMID 41275334.
 |  |
